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Addition of monoclonal antibodies (UCHTl) directed against the antigen receptor/CD3 complex or the addition of the 
mitogens concanavalin A or phytohemagglutinin to human T lymphoblasts induced an elevation of the cytosolic free 
calcium concentration ([Ca*‘li) as monitored by the fluorescence of the intracellular fura-2. The rise in [Ca*‘ll induced 
by these agents was effectively inhibited by staurosporine, an agent which inhibits protein kinase (PK)C and PKA. Con- 
versely the PKC activator 12-O-tetradecanoyl phorbol-13-acetate decreased the delay and accelerated the rate of elevation 
of [Caz+], induced by the mitogens and UCHTl. Increasing ths concentration of CAMP or cGMP in the T lymphoblasts 
had no effect on agonist-induced elevation of [Caz’li. Our data indicate that PKC can exert a positive feedback on the 
level of cytosolic Ca*+ in T lymphocytes, in contrast to what has been observed with other cells. 
Caz+; Fura-2; Staurosporine; T lymphocyte 
1. INTRODUCTION 
T lymphocyte activation via the antigen recep- 
tor/CD3 complex results in elevation of cytosolic 
free calcium levels ([Ca2’]i) and protein kinase C 
(PKC) stimulation [1,2]. These two signals 
synergise to induce the expression of IL-2 recep- 
tors, IL-2 production and hence T cell growth. The 
initial increase in [Ca2+]i is due to the mobilisation 
of intracellular Ca2+ and is apparently mediated by 
Ins 1,4,5-P3, a product of the hydrolysis of 
phosphatidylinositol 4,Sbisphosphate [3-71. The 
antigen receptor/CD3 mediated elevation of 
[Ca’+]i is then sustained by influx of extracellular 
Ca2+ probably through voltage-independent Ca2+ 
Correspondence nddress: J. Westwick, Department of Phar- 
macology, Royal College of Surgeons, Lincoln’s Inn Fields, 
London WCZA 3PN, England 
Abbreviations: TPA, 12-0tetradecanoyl phorbol-13-acetate; 
Con A, concanavalin A; PHA, phytohemagglutinin; IL-2, in- 
terleukin 2; [Ca’+]i, cytosolic free calcium concentration; 
PKA(C), protein kinase A(C); Ins 1,4-Pz, inositol 
1,4-bisphosphate; Ins 1,4,5-P3, inositol 1,4,5_trisphosphate; Ins 
1,3,4,5-P4, inositol 1,3,4,5_tetrakisphosphate 
channels, which can also be activated by Ins 
1,4,5-P3 [3,8]. 
There is a requirement for a prolonged ongoing 
elevation of the [Ca2+]i for T cell activation [2]. 
Consequently, it is predicted that feedback 
mechanisms that regulate ligand-mediated altera- 
tions in Ca2+ homeostasis would have profound ef- 
fects on the T cell activation response. In this 
respect, PKC appears to have a feedback role in 
the T cell, since activation of PKC results in down- 
regulation of the surface expression of the antigen 
receptor/CD3 complex [9-121. Moreover, there 
are reports that activation of PKC inhibits the 
elevation of [Ca2+]i induced by stimulation of the 
vasopressin and bombesin receptors on Swiss 3T3 
cells and the thrombin receptor on human platelets 
[ 13,141. However, other calcium-mobilising recep- 
tors such as the platelet-derived growth factor 
receptor in Swiss 3T3 cells are not inhibited by 
PKC [13]. 
The aim of the present study therefore was to 
determine the role of PKC in the modulation of T 
cell [Ca2+]i following stimulation of the antigen 
receptor/CD3 complex. 
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2. EXPERIMENTAL 
Peripheral blood mononuclear cells were separated by Ficoll- 
Paque (Pharmacia) gradient centrifugation of fresh human 
blood as described [15], from which human T lymphoblasts 
were prepared according to Smith and Cantrell [16]. 
T lymphoblasts were suspended at 10’ cells/ml in RPMI-1640 
medium supplemented with 10% heat-inactivated fetal calf 
serum and incubated for 30 min at 37°C with 2.5 pM fura- 
acetoxymethyl ester (fura-2/AM). After incubation, the cells 
were washed three times in 20 ml calcium-free, Hepes-buffered 
Tyrode solution and finally resuspended at 1 x lo6 cells/ml in 
Hepes buffer, as in [17]. 
Aliquots of cells (1 ml) suspended in Hepes-buffered Tyrode 
solution were dispensed into disposable cuvettes and the exter- 
nal Ca*+ concentration ([Ca”],) adjusted to 1 mM with CaCl2. 
Cells were allowed to equilibrate at 37°C for 2 min before drug 
addition to the cell-containing cuvettes. The [Ca2+]i of T lym- 
phoblasts was determined by fluorescence, as described in [ 171. 
The following chemicals were obtained from the sources in- 
dicated: fura-Z/AM from Molecular Probes (Eugene, OR); 
Con A from Sigma (Poole, England); PHA from Wellcome 
(Beckenham, England); staurosporine from Fluorochem (UK); 
UCHTl was from Imperial Cancer Research Fund (London, 
England). 
3. RESULTS 
The antigen receptor/CD3 complex can be trig- 
gered by antibodies reactive with the CD3 antigen 
[l]. Thus, addition of the CD3 monoclonal an- 
tibody UCHTl (2.4-24yg/ml), or the polyclonal 
a 
T cell mitogens Con A (3-300 ,ug/ml) and PHA 
(0.6-60 pg/ml) to fura-2-loaded human T lym- 
phoblasts suspended in Hepes-buffered Tyrode 
solution containing 1 mM [Ca’+],, produced eleva- 
tion of [Ca2+]i above basal levels of 166 f 17 nM 
(n = 30) to approx. 200-2000 nM depending on 
dose (fig. 1). As can be seen in fig. 1, increasing the 
dose of UCHTl or either mitogen reduces the 
delay in response, accelerates the rate of elevation 
and increases the peak calcium signal. 
The construction of dose-response curves for 
each of the agonists, allowed the selection of sub- 
optimal doses of UCHTl (8 pg/ml), Con A 
(30pg/ml) and PHA (20 pg/ml), all of which 
elevated the [Ca2+]i to approx. 600 nM. To ex- 
amine the role of PKC, the T lymphoblasts were 
pretreated with staurosporine, an agent which in- 
hibits PKC and PKA [18]. 1 min pre-treatment 
with staurosporine (9-300 nM) resulted in a dose- 
dependent inhibition of sub-optimal UCHTl, 
Con A and PHA-induced elevation of [Ca2+]i (figs 
132). The IGO values for inhibition by 
staurosporine of sub-optimal UCHTl, Con A and 
PHA-induced elevation of [Ca2+]i were 66 + 18, 91 
f 7 and 82 +- 10 nM, respectively. A similar range 
of staurosporine concentrations (9-300 nM) had 
no effect on resting [Ca2+]i. 
Conversely, incubation of the T lymphoblasts 
with the PKC activator TPA (0.48-48 nM) 10 min 
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Fig.1. The effect of (a) UCHTl, Con A and PHA on T lymphoblast [Ca*+]i and (b) 1 min pre-treatment with staurosporine on 
elevations of T lymphoblast [Ca’+]i induced by suboptimal UCHTl (8 pg/ml), Con A (30 pg/ml) and PHA (20 @g/ml). The non-linear 
vertical scale is the result of transforming fluorescent output to T lymphoblast [Ca’+]i. The traces were obtained from one experiment 
but are representative of four other experiments. 
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Fig.2. Dose-response curves of inhibition by I min pre- 
treatment with staurosporine of elevations of T lymphoblast 
[Ca*+]i induced by UCHTl (8 fig/ml), Con A (30 ,ug/ml), and 
PHA (20,ugIml). Each point represents the mean f SE of 
determinations performed in four separate experiments. 
prior to the addition of UCHTl or Con A resulted 
in a decreased elay, accelerated rate of elevation 
and an enhanced peak calcium signal compared to 
TPA vehicle-treated cells @ < 0.05; fig.3a-c). Fur- 
thermore, pre-treatment of T lymphoblasts for 
10 min with another PKC activator, phorbol 
12,13-dibutyrate (50 nM), produced an essentially 
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similar enhancement of ligand-induced elevation 
of [Ca2+]i compared to vehicle-treated cells (p < 
0.05, n = 5; not shown). In contrast, pre-treatment 
of the T lymphoblasts with 4,&phorbol 
(4.8-480 nM, n = 4) which does not activate PKC, 
did not modify sub-optimal UCHTl or Con A- 
induced elevation of [Ca2+]i. 
To lend support to the notion that staurosporine 
was inhibiting PKC in these studies, TPA pretreat- 
ment prior to the addition of staurosporine 
resulted in a reduction of the inhibitory effect of 
staurosporine on PI-IA-induced [Ca2+]i elevation 
(fig.3d). 
To examine the possibility that the staurosporine 
effects could be mediated by CAMP- or cGMP- 
dependent kinases, the following experiments were 
performed to determine the role of CAMP and 
cGMP in the modulation of T cell [Ca2+]i. The 
cells were pretreated for l-10 min with either for- 
skolin (lo- 100 PM), an adenyl cyclase activator; 
or 8-bromo-CAMP (50 ,uM), a cell-permeant 
CAMP analog; or sodium nitroprusside (30-150 
PM), a guanyl cyclase activator; or S-bromo cGMP 
(50 PM). These compounds had no significant ef- 
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Fig.3. Effect of 1 min (a) or 10 min (b) pretreatment with vehicle or TPA (48 nM) on suboptimal Con A (30 rg/ml)-induced elevation 
of T lymphoblast [Cazf]i; (c) effect of 1 min pretreatment with vehicle or TPA (48 nM) on suboptimal UCHTl (24 /g/ml)-induced 
elevation of T lymphoblast [Ca’+]r; (d) effect of pretreatment for 1 min with staurospermine vehicle (Vi) and for 2 min with TPA 
vehicle (VZ), or with 90 nM staurosporine (SS) and VZ, or with SS and 48 nM TPA on PHA (20/rg/ml)-induced elevation of T 
lymphoblast [Cazf]:. The non-linear vertical scale is the result of transforming fhrorescent output to T lymphoblast [Ca’+]i. The traces 
were obtained from one experiment but are representative of four other experiments. 
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feet 0, > 0.05) on sub-optimal UCHTI and PHA- 
induced elevation of [Ca2+]i. Accordingly, 
staurosporine effects on CAMP- or cGMP- 
dependent kinases are unlikely to influence T cell 
[Ca’+]i. 
4. DISCUSSION 
The present data indicate a positive feedback 
role for PKC in the regulation of [Ca2+]i in T lym- 
phocytes, since activation of PKC enhances, while 
inhibition of PKC prevents ligand-induced eleva- 
tion of [Ca2+]i. The marked enhancement of 
receptor-operated elevation of [Ca’+]i via PKC is 
surprising as PKC stimulation immediately in- 
creases the rate of internalisation of the antigen 
receptor/CD3 complex, thereby decreasing its sur- 
face levels 19-121. Thus, PKC activation appears 
to produce a considerable facilitation of the 
calcium elevation that occurs via stimulation of the 
remaining cell surface located receptors. 
A positive feedback role for PKC in the modula- 
tion of cytosolic calcium appears unique to T lym- 
phocytes, since stimulation of PKC in platelets, 
polymorphonuclear cells, leukemic basophils, 
pituitary cells, PC12 cells, hepatocytes or B lym- 
phocytes (for references see [14,19]) inhibits 
receptor-operated elevation of [Ca2+]i. In platelets 
the inhibitory effect of PKC on the calcium- 
mobilising activity of receptors is possibly ex- 
plained by a PKC-induced reduction in Ins 
1,4,5-P3 levels via at least two mechanisms: inhibi- 
tion of phospholipase C [20] and thus reduced Ins 
1,4,5-P3 formation and also increased conversion 
of Ins 1,4,5-P3 to Ins I,4-P2 [21]. 
It remains to be determined therefore whether 
the effects of PKC on T cell intracellular calcium 
are explained by its effects on the metabolism of 
phosphoinositides. However, there are reports that 
PKC can stimulate the PI cycle to produce in- 
creased levels of phosphatidylinositol 4,5-bisphos- 
phate [22]. In addition, Imboden and Pattison [23] 
have recently demonstrated that PKC stimulation 
leads to an increased conversion of Ins 1,4,5-P3 to 
Ins 1,3,4,5-P4. Although the latter does not 
mobilise intracellular calcium, there is evidence to 
suggest hat Ins 1,3,4-P3 and Ins 1,3,4,5-P4 work 
in concert to promote influx of calcium across the 
plasma membrane [24]. It is tempting to speculate 
that this could be the mechanism of the enhanced 
elevation of [Ca’+]i reported in the present study. 
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